PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?

Felekos, Ioannis and Karamasis, Grigoris V. and Pavlidis, Antonis N. (2021) PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low? Current Pharmaceutical Design, 27 (8). pp. 1008-1014. ISSN 1873-4286

Full text not available from this repository.
Official URL: https://doi.org/10.2174/1381612826666200617170252

Abstract

Diabetic patients are considered to be at high risk for the development of atherosclerotic disease. Management of hypercholesterolemia is of paramount importance to optimize cardiovascular outcomes in this subset of patients and statins are regarded as the mainstay of treatment. However, the recent advent of PCSK-9 inhibitors has provided a useful alternative in the management of dyslipidemia, especially when statins cannot be tolerated or when hypolipidemic targets cannot be achieved. In this review, we discuss current trends in their use, and we focus on their role in the management of diabetic dyslipidemia.

Item Type: Journal Article
Keywords: PCSK9 inhibitors, atherosclerotic disease, diabetes, dyslipidemia, hypercholesterolemia, hypolipidemic
Faculty: Faculty of Health, Education, Medicine & Social Care
Depositing User: Lisa Blanshard
Date Deposited: 29 Apr 2021 14:53
Last Modified: 09 Sep 2021 16:04
URI: https://arro.anglia.ac.uk/id/eprint/706540

Actions (login required)

Edit Item Edit Item